Trial Profile

A phases I/II of FLD-103, an intralesional treatment against basal cell carcinoma (BCC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2024 Status changed from planning to recruiting, according to a Feldan therapeutic media release.
31 Oct 2024 According to a Feldan therapeutic media release, company announced its first patient being dosed in Phase 1/2a clinical study of Lead development candidate FLD-103; an intralesional injection intended to provide an alternative to surgery to patients diagnosed with basal cell carcinoma (BCC).
04 Sep 2024 According to a Feldan therapeutic media release, the company received a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarite FTQ (Fonds) proceeds from this trial will be used to complete this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com